Northern Trust Corp increased its position in Editas Medicine, Inc. (NASDAQ:EDIT) by 245.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 373,149 shares of the company’s stock after buying an additional 265,273 shares during the quarter. Northern Trust Corp owned 0.92% of Editas Medicine worth $6,261,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of EDIT. Bank of New York Mellon Corp increased its stake in shares of Editas Medicine by 53.3% in the first quarter. Bank of New York Mellon Corp now owns 63,490 shares of the company’s stock worth $1,418,000 after buying an additional 22,061 shares during the period. Vanguard Group Inc. increased its position in Editas Medicine by 47.0% during the 1st quarter. Vanguard Group Inc. now owns 1,935,173 shares of the company’s stock valued at $43,193,000 after purchasing an additional 618,789 shares during the period. Geode Capital Management LLC increased its position in Editas Medicine by 4.7% during the 1st quarter. Geode Capital Management LLC now owns 119,376 shares of the company’s stock valued at $2,664,000 after purchasing an additional 5,397 shares during the period. Morgan Stanley increased its position in Editas Medicine by 48.3% during the 1st quarter. Morgan Stanley now owns 308,909 shares of the company’s stock valued at $6,895,000 after purchasing an additional 100,585 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its position in Editas Medicine by 8.4% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 42,150 shares of the company’s stock valued at $941,000 after purchasing an additional 3,249 shares during the period. 67.17% of the stock is currently owned by institutional investors.

WARNING: “Northern Trust Corp Has $6.26 Million Position in Editas Medicine, Inc. (EDIT)” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/northern-trust-corp-has-6-26-million-position-in-editas-medicine-inc-edit/1704029.html.

Shares of Editas Medicine, Inc. (NASDAQ EDIT) opened at $23.55 on Wednesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 10.12 and a current ratio of 10.12. Editas Medicine, Inc. has a 1 year low of $13.12 and a 1 year high of $29.20.

Editas Medicine (NASDAQ:EDIT) last released its earnings results on Tuesday, November 7th. The company reported ($0.64) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.04). The business had revenue of $6.28 million during the quarter, compared to analysts’ expectations of $2.66 million. Editas Medicine had a negative return on equity of 70.19% and a negative net margin of 1,127.03%. The firm’s quarterly revenue was up 553.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.59) earnings per share. equities research analysts forecast that Editas Medicine, Inc. will post -2.92 EPS for the current year.

EDIT has been the topic of a number of research analyst reports. ValuEngine downgraded shares of Editas Medicine from a “hold” rating to a “sell” rating in a research report on Wednesday, October 25th. Zacks Investment Research downgraded shares of Editas Medicine from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Cann reissued a “hold” rating on shares of Editas Medicine in a research report on Tuesday, November 7th. J P Morgan Chase & Co set a $27.00 price objective on shares of Editas Medicine and gave the company a “hold” rating in a research report on Wednesday, August 9th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $28.00 price objective (up from $27.00) on shares of Editas Medicine in a research report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $26.73.

In other news, insider Katrine Bosley sold 8,333 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $23.64, for a total value of $196,992.12. Following the sale, the insider now directly owns 1,393,322 shares of the company’s stock, valued at approximately $32,938,132.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 43,332 shares of company stock worth $946,504 over the last ninety days. Insiders own 19.40% of the company’s stock.

Editas Medicine Profile

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine, Inc. (NASDAQ:EDIT).

Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.